Stock Market Reviews

Read and share opinions on AVDL (Avadel Pharmaceuticals plc) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

Latest News

• Assessing Avadel Pharmaceuticals (AVDL) Valuation After Strong 1-Year Share Price Performance
  Dec 20, 2025
• Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
  Dec 18, 2025
• Announcement relating to despatch of Rule 15 proposal
  Dec 5, 2025
• Avadel Pharmaceuticals (AVDL): Evaluating Valuation After Recent Share Price Surge
  Nov 30, 2025
• Avadel (AVDL) Drops 6.7% on Lack of Leads
  Nov 27, 2025
• Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
  Nov 19, 2025
• Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
  Nov 18, 2025

AVDL News

• Form 8.3
  BOSTON, December 29, 2025-- Ap27
  Dec 29, 2025
• Form 8.3
  BOSTON, December 29, 2025-- Ap27
  Dec 29, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing23rd December 2025 2. INTERESTS AND SHORT POSITIONS(11
  Dec 24, 2025
• Form 8.3
  BOSTON, December 23, 2025-- Ap27
  Dec 23, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing22nd December 2025 2. INTERESTS AND SHORT POSITIONS(11
  Dec 23, 2025
• Form 8.3
  BOSTON, December 22, 2025-- Ap27
  Dec 22, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing19th December 2025 2. INTERESTS AND SHORT POSITIONS(11
  Dec 22, 2025
• Assessing Avadel Pharmaceuticals (AVDL) Valuation After Strong 1-Year Share Price Performance
  Avadel Pharmaceuticals (AVDL) has quietly turned into a strong performer this year, and the stock’s recent moves are getting more attention as investors weigh what its narcolepsy franchise could mean for future growth. See our latest analysis for Avadel Pharmaceuticals. At a share price of $21.47, Avadel’s 90 day share price return of 32.53 percent and 1 year total shareholder return of 108.24 percent suggest momentum is still building as investors increasingly price in narcolepsy growth...
  Dec 20, 2025
• Form 8.3
  BOSTON, December 19, 2025-- Ap27
  Dec 19, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing18th December 2025 2. INTERESTS AND SHORT POSITIONS(11
  Dec 19, 2025
• Form 8.3
  BOSTON, December 18, 2025-- Ap27
  Dec 18, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing17th December 2025 2. INTERESTS AND SHORT POSITIONS(11
  Dec 18, 2025
• Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
  - Data expected in Q2 2026 - DUBLIN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced the completion of patient enrollment in REVITALYZ, a Phase 3 trial evaluating LUMRYZTM (sodium oxybate) extended-release oral suspension as a potential treatment for idiopathic hypersomnia (IH). REVITALYZ is a double-blind, placebo-controlled, randomized withdrawal, multicenter Phase 3 trial d
  Dec 18, 2025
• Form 8.3
  BOSTON, December 17, 2025-- Ap27
  Dec 17, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing16th December 2025 2. INTERESTS AND SHORT POSITIONS(11
  Dec 17, 2025
• Form 8.3
  BOSTON, December 16, 2025-- Ap27
  Dec 16, 2025
• Form 8.3
  BOSTON, December 15, 2025-- Ap27
  Dec 15, 2025
• Form 8.3 - Amendment
  LONDON, December 15, 2025-- Ap27
  Dec 15, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing12th December 2025 2. INTERESTS AND SHORT POSITIONS(11
  Dec 15, 2025
• Form 8.3
  BOSTON, December 12, 2025-- Ap27
  Dec 12, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing11th December 2025 2. INTERESTS AND SHORT POSITIONS(11
  Dec 12, 2025
• Form 8.3
  BOSTON, December 11, 2025-- Ap27
  Dec 11, 2025
• Form 8.3
  BOSTON, December 10, 2025-- Ap27
  Dec 10, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing9th December 2025 2. INTERESTS AND SHORT POSITIONS(110
  Dec 10, 2025
• Form 8.3
  BOSTON, December 09, 2025-- Ap27
  Dec 9, 2025
• Form 8.3 - Amendment
  LONDON, December 09, 2025-- Ap27
  Dec 9, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing8th December 2025 2. INTERESTS AND SHORT POSITIONS(110
  Dec 9, 2025
• Form 8.3
  LONDON, December 08, 2025-- Ap27
  Dec 8, 2025
• How Recent Deal Developments Are Reshaping The Avadel Pharmaceuticals Investment Story
  Avadel Pharmaceuticals' fair value estimate has been nudged slightly lower to about $20.94 per share from roughly $21.06, even as the discount rate holds near 7.34 % and revenue growth expectations hover around 24.1 % annually. This subtle recalibration reflects a more balanced Street narrative as the Alkermes deal, competing interest from Lundbeck, and debate over Lumryz's long term durability and CVR upside reshape the stock's risk reward profile. Read on to see how you can stay on top of...
  Dec 6, 2025
• Form 8.3
  LONDON, December 05, 2025-- Ap27
  Dec 5, 2025
• Has Avadel’s 115% Rally in 2024 Already Priced In Its Narcolepsy Breakthrough?
  Wondering if Avadel Pharmaceuticals is still a smart buy after its big run, or if the easy money has already been made? Let us unpack what the current price really implies about its long term value. Over the last week the stock has barely moved at around -0.2%, but zoom out and Avadel is up 13.0% over 30 days, 94.1% year to date, and a striking 114.6% over the past year, which clearly signals shifting market expectations. Much of that optimism has been tied to regulatory and...
  Dec 5, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing4th December 2025 2. INTERESTS AND SHORT POSITIONS(110
  Dec 5, 2025
• Announcement relating to despatch of Rule 15 proposal
  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 15(C) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors of Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company inc
  Dec 5, 2025
• Form 8.3
  LONDON, December 04, 2025-- Ap27
  Dec 4, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing3rd December 2025 2. INTERESTS AND SHORT POSITIONS(110
  Dec 4, 2025
• Form 8.3
  LONDON, December 03, 2025-- Ap27
  Dec 3, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing2nd December 2025 2. INTERESTS AND SHORT POSITIONS(110
  Dec 3, 2025
• Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 17(B) (AS AMENDED BY SECTION 3 OF APPENDIX 4) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors of Avadel Pharmaceuticals plc (Nas
  Dec 3, 2025
• Form 8.3
  LONDON, December 02, 2025-- Ap27
  Dec 2, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing1st December 2025 2. INTERESTS AND SHORT POSITIONS(110
  Dec 2, 2025
• Form 8.3
  LONDON, December 01, 2025-- Ap27
  Dec 1, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing28th November 2025 2. INTERESTS AND SHORT POSITIONS(11
  Dec 1, 2025
• Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting
  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 17(A) (AS AMENDED BY SECTION 3 OF APPENDIX 4) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) FOR IMMEDIATE RELEASE DUBLIN, Dec. 01, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors of Avadel Ph
  Dec 1, 2025
• Avadel Pharmaceuticals (AVDL): Evaluating Valuation After Recent Share Price Surge
  Avadel Pharmaceuticals (AVDL) stock has caught the attention of investors following recent trading momentum. With shares finishing yesterday at $21.49, many are watching closely to see if near-term trends continue in the coming weeks. See our latest analysis for Avadel Pharmaceuticals. Building on a strong run this year, Avadel Pharmaceuticals has surged, delivering a 95.36% year-to-date share price return and a 94.3% total shareholder return over the past twelve months. Recent momentum...
  Nov 30, 2025
• Form 8.3
  BOSTON, November 27, 2025-- Ap27
  Nov 27, 2025
• Avadel (AVDL) Drops 6.7% on Lack of Leads
  We recently published 10 Stocks Losing Their Bite Before Thanksgiving. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the worst-performing stocks on Wednesday. Avadel declined by 6.67 percent on Wednesday to end at $21.40 apiece as investors sold off positions amid the lack of fresh catalysts to boost buying. In recent developments, Avadel Pharmaceuticals plc (NASDAQ:AVDL) […]
  Nov 27, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing26th November 2025 2. INTERESTS AND SHORT POSITIONS(11
  Nov 27, 2025
• Form 8.3
  BOSTON, November 26, 2025-- Ap27
  Nov 26, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing25th November 2025 2. INTERESTS AND SHORT POSITIONS(11
  Nov 26, 2025
• Form 8.3
  BOSTON, November 25, 2025-- Ap27
  Nov 25, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing24th November 2025 2. INTERESTS AND SHORT POSITIONS(11
  Nov 25, 2025
• Form 8.3
  BOSTON, November 24, 2025-- Ap27
  Nov 24, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing21st November 2025 2. INTERESTS AND SHORT POSITIONS(11
  Nov 24, 2025
• Form 8.3
  BOSTON, November 21, 2025-- Ap27
  Nov 21, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing20th November 2025 2. INTERESTS AND SHORT POSITIONS(11
  Nov 21, 2025
• Form 8.3
  BOSTON, November 20, 2025-- Ap27
  Nov 20, 2025
• ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
  Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
  Nov 20, 2025
• 3 Prominent Stocks Estimated To Be Up To 35.1% Below Intrinsic Value
  As the U.S. stock market shows signs of recovery with major indexes snapping recent losing streaks, investors are keeping a close watch on tech giants like Nvidia for insights into broader market trends. In this environment, identifying undervalued stocks can provide opportunities for growth, particularly when these equities are trading significantly below their intrinsic value.
  Nov 20, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing19th November 2025 2. INTERESTS AND SHORT POSITIONS(11
  Nov 20, 2025
• Form 8.3
  BOSTON, November 19, 2025-- Ap27
  Nov 19, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing18th November 2025 2. INTERESTS AND SHORT POSITIONS(11
  Nov 19, 2025
• Sector Update: Health Care Stocks Mixed in Afternoon Trading
  Health care stocks traded mixed Wednesday afternoon, with the NYSE Health Care Index up 0.1% and the
  Nov 19, 2025
• Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
  Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional cash payment of $1.50 per share, conting
  Nov 19, 2025
• Alkermes escalates bidding war; US biotech risks ‘falling behind’ China
  A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.
  Nov 19, 2025
• Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With Lundbeck
  Alkermes upped its bid on Avadel to $2.37 billion on Wednesday, coming in with the "superior proposal" vs. Lundbeck's unexpected pitch.
  Nov 19, 2025
• Form 8.3
  BOSTON, November 18, 2025-- Ap27
  Nov 18, 2025
• Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
  AVDL's board calls Lundbeck's higher $23-per-share bid superior to its Alkermes deal, triggering a critical five-day response window.
  Nov 18, 2025
• Examining Avadel Pharmaceuticals After FDA Approval Buzz and 109% Year-to-Date Rally
  Wondering if Avadel Pharmaceuticals could offer real value for your portfolio? You are not alone, especially with the stock grabbing more attention in today’s market. Shares have surged, jumping 23.1% in just the last week and soaring an impressive 109.3% year-to-date. This performance is putting growth potential and shifting investor sentiment in the spotlight. The latest move comes amid FDA approval buzz for Avadel’s key sleep disorder treatment and growing optimism as...
  Nov 18, 2025
• Form 8.3
  LONDON, November 17, 2025-- Ap27
  Nov 17, 2025
• Form 8.3
  BOSTON, November 17, 2025-- Ap27
  Nov 17, 2025
• Form 8.3 - Avadel Pharmaceuticals plc
  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to whichthe dealings being disclosed relate (Note 2)$0.01 ordinary sharesDate of dealing14th November 2025 2. INTERESTS AND SHORT POSITIONS(11
  Nov 17, 2025
• Needham Reiterates a Hold Rating on Avadel Pharmaceuticals (AVDL)
  ​Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the Hottest Small Cap Stocks to Buy Now. On November 5, Ami Fadia from Needham reiterated a Hold rating on Avadel Pharmaceuticals plc (NASDAQ:AVDL) without disclosing any price target. ​The rating follows the company’s Q3 2025 results released on November 4. During the quarter, the company grew its […]
  Nov 17, 2025
• Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”
  THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND IS NOT AN ANNOUNCEMENT OF A FIRM INTEN
  Nov 17, 2025
• Avadel (AVDL) Gets 26% Boost on Takeover Bid
  We recently published 10 Market Movers That Made Millionaires in a Week. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the best-performing stocks of the past trading week. Avadel jumped by 26.06 percent week-on-week as investors loaded up portfolios after receiving a new takeover interest from a new pharmaceutical giant. Last Friday, Avadel Pharmaceuticals plc (NASDAQ:AVDL) […]
  Nov 16, 2025
• Avadel (AVDL) Soars to 10-Year High on Brewing Bidding War
  We recently published Lackluster Market? Not for These 10 Soaring Stocks. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the best-performing stocks on Friday. Avadel extended its winning streak to a 5th straight day on Friday to hit a new 10-year high as investor sentiment was boosted by its receipt of a new acquisition proposal which […]
  Nov 15, 2025
• A Fresh Look at Avadel Pharmaceuticals (AVDL) Valuation After Share Price Rally
  Avadel Pharmaceuticals (AVDL) shares have been on the move this month, catching the attention of investors with a steady gain over the past several weeks. The company’s performance has been impressive and has outpaced many peers in the sector. See our latest analysis for Avadel Pharmaceuticals. This surge follows a breakout run for Avadel, with the 30-day share price return hitting 55.41% and building on an even more remarkable year-to-date rally of 114.18%. Momentum is clearly on the rise,...
  Nov 15, 2025
• Exchange-Traded Funds, Equity Futures Pre-Bell Friday as Rate-Cut Hopes Fade
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 1.1% and the actively tr
  Nov 14, 2025
• Alkermes Response to Avadel Announcement
  Alkermes plc ("Alkermes") (Nasdaq: ALKS) notes the announcement made by Avadel Pharmaceuticals plc ("Avadel") regarding a possible offer by H. Lundbeck A/S ("Lundbeck") to acquire all the issued and to be issued ordinary shares of Avadel (the "Lundbeck Alternative Offer").
  Nov 14, 2025
• Update: Avadel Shares Rise After Receipt of Unsolicited Acquisition Proposal From Lundbeck
  (Updates with Avadel Pharmaceuticals' latest stock move in the headline and the first paragraph.)
  Nov 14, 2025
• Avadel Receives Unsolicited Proposal from Lundbeck
  THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND IS NOT AN ANNOUNCEMENT OF A FIRM INTEN
  Nov 14, 2025
• Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid
  A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center and prospective acquirer Alkermes facing off with Lundbeck.
  Nov 14, 2025
• H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
  The unsolicited bid—worth up to $2.25 billion—potentially upends Avadel’s deal to be acquired by Alkermes.
  Nov 14, 2025
• Avadel Pharmaceuticals Receives Unsolicited Acquisition Proposal From Lundbeck
  Avadel Pharmaceuticals (AVDL) said Friday that it received an unsolicited acquisition proposal from
  Nov 14, 2025
• To Wall Street, a new bidding war puts Alkermes in a tough spot
  Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying significantly more than it had hoped.
  Nov 14, 2025
• Avadel Pharmaceuticals (AVDL): Widening Losses Reinforce Bearish Narratives, Profitability Seen as Key Catalyst
  Avadel Pharmaceuticals (AVDL) reported continued unprofitability, with losses widening at a rate of 12.4% per year over the past five years and no improvement in profit margins. Looking ahead, the company is expected to deliver robust annual earnings growth of 40.12% and revenue growth of 15.6%, both outpacing the broader US market’s 10.5% forecast. Investors are watching the company’s expected transition to profitability within three years as a key catalyst in the turnaround story. See our...
  Nov 6, 2025
• FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc
  U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ap9 FORM 8.1(a) & (b)(Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1. KEY INFORMATION (a) Full name of discloser:Avadel Pharmaceuticals plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust,
  Nov 5, 2025
• FORM 8.1(a) & (b) (Opening Position Disclosure)
  Alkermes plc (Nasdaq: ALKS):
  Nov 5, 2025
• Form 8.3 - Amendment
  LONDON, November 05, 2025-- Ap27
  Nov 5, 2025
• New Strong Sell Stocks for Nov. 5
  AVDL, EPM and FMC have been added to the Zacks Rank #5 (Strong Sell) List on Nov.5, 2025
  Nov 5, 2025
• Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  – Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to September 30, 2024 – – Announced global settlement of all litigation with Jazz Pharmaceuticals, Inc. (“Jazz”) – – Acquisition by Alkermes plc (“Alkermes”) expected to close in first quarter 2026 – DUBLIN, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutica
  Nov 4, 2025

AVDL Reviews

• HedgeMeNot

  Dec 30, 2025

  $AVDL Taking their shot, but need to show more fire!

  Sell

• MemeInvestor

  Dec 30, 2025

  $AVDL Pharmaceuticals feeling like a magic show—now you see it, now you don’t! Hope the rabbit isn't stuck in the hat!

  Buy

• TheLongPlay

  Dec 29, 2025

  $AVDL Pharma game strong, they’re pushing innovation like nobody's business!

  Buy

• PaperHandsGone

  Dec 29, 2025

  $AVDL They’re cooking up some fresh ideas in the health game—definitely one to watch!

  Buy

• EarningsSync

  Dec 28, 2025

  $AVDL The pharmaceutical world is never dull, but this one feels particularly chaotic. With breakthroughs on the horizon, the stakes are high—can they deliver without crashing and burning?

  Buy

• TradeTracer

  Dec 28, 2025

  $AVDL This company is making substantial strides in the pharmaceutical sector, focusing on innovative treatments that address significant unmet medical needs. Its commitment to research and development positions it well for potential breakthroughs and market opportunities.

  Buy

• BullishBard

  Dec 28, 2025

  $AVDL This stock is like a caffeine boost for your portfolio—can’t guarantee it won’t keep you up at night!

  Buy

• StonkPhantom

  Dec 27, 2025

  $AVDL With potential breakthroughs just around the corner, the pressure is mounting. Success could lead to a major leap, but the stakes are sky-high!

  Buy

• AlgoAce

  Dec 26, 2025

  $AVDL This stock is like a pharmacy on game day—loaded with prescriptions for success, just hoping it doesn’t run out of stock!

  Buy

• ChartFang

  Dec 25, 2025

  $AVDL Focused on drug development, this company is making strides in the pharmaceutical industry with its innovative therapies aimed at treating rare diseases. Its commitment to research and development may yield significant advancements in healthcare.

  Buy

• WallStreetGrim

  Dec 25, 2025

  $AVDL This biotechnology firm is at the forefront of developing innovative therapies, showcasing a commitment to addressing significant health challenges. Its pipeline of products is promising and could lead to impactful market contributions.

  Buy

• BullishBard

  Dec 25, 2025

  $AVDL This company is like that one friend who always brings snacks to the party—definitely a reason to stick around!

  Buy

• BuyLowBro

  Dec 24, 2025

  $AVDL Like that friend who always brings snacks to the party, this stock knows how to keep the good vibes flowing!

  Sell

• CodeAndCapital

  Dec 24, 2025

  $AVDL If this stock were a superhero, it’d be the one with the coolest gadgets but always gets caught in traffic.

  Sell

• BullishMyth

  Dec 24, 2025

  $AVDL With pharmaceutical advancements racing forward, is this company on the brink of a breakthrough or on the edge of irrelevance? The tension is palpable.

  Buy

• CryptoCobra

  Dec 23, 2025

  $AVDL Think of this stock as that quirky friend who always has the best stories to tell – they might surprise you!

  Buy

• TrendHunter

  Dec 22, 2025

  $AVDL Innovation? More like stuck in the past.

  Sell

• TickerTakedown

  Dec 22, 2025

  $AVDL This stock is like a magician – making problems disappear faster than you can say 'abracadabra'!

  Buy

• LiquidityLord

  Dec 22, 2025

  $AVDL Positioned at the forefront of the pharmaceutical sector, this firm is making significant strides in addressing critical health challenges. Its robust pipeline and strategic partnerships are indicative of a forward-thinking approach to innovation.

  Buy

• ChartFang

  Dec 21, 2025

  $AVDL With a promising pipeline of pharmaceutical products, this firm is on the forefront of addressing critical health challenges. Its research and development efforts indicate a strong future potential within the competitive biotech landscape.

  Buy

• TheQuantEdge

  Dec 21, 2025

  $AVDL What a rollercoaster ride! You have to keep your eyes peeled—any small hint of news could send it soaring or crashing!

  Buy

• StonkDestroyer

  Dec 21, 2025

  $AVDL A pharmaceutical company with about as much promise as a wet sock.

  Sell

• CashCraze

  Dec 21, 2025

  $AVDL With a focus on advancing its treatment options, this firm is addressing critical healthcare needs. Their recent advancements and strategic partnerships indicate a strong trajectory in the pharmaceutical sector.

  Buy

• LiquidityLord

  Dec 20, 2025

  $AVDL This firm is dedicated to developing transformative therapies and demonstrates a strong commitment to addressing crucial healthcare challenges. Its strategic partnerships and focus on clinical efficacy suggest a positive trajectory in the pharmaceutical landscape.

  Buy

• PortfolioPunk

  Dec 20, 2025

  $AVDL Chasing elusive profits like it's a game of hide and seek.

  Sell

• CapitalVortex

  Dec 19, 2025

  $AVDL The pharmaceutical race is relentless, and this company is feeling the heat. Can they deliver breakthrough results when every second counts? The pressure is mounting!

  Sell

• GainSurge

  Dec 19, 2025

  $AVDL This pharmaceutical play is edging closer to either groundbreaking results or crashing waves of disappointment. The stakes are high, and the clock is ticking. Will they deliver?

  Buy

• TheChartCode

  Dec 18, 2025

  $AVDL This company’s got more potential than my phone’s battery at 100%! Don’t sleep on it!

  Buy

• OptionMatrix

  Dec 18, 2025

  $AVDL This pharmaceutical entity is actively engaging in the development of essential health products, navigating a complex regulatory environment while aiming to address critical patient needs, suggesting potential for positive impact.

  Buy

• StonkDestroyer

  Dec 18, 2025

  $AVDL Trying hard to be relevant but missing the mark.

  Sell

• RocketDividend

  Dec 17, 2025

  $AVDL Pharma moves like a boss, tackling big health challenges with flair!

  Buy

• AlphaRift

  Dec 17, 2025

  $AVDL With a focus on sleep medicine and evolving therapies, the company is poised to make significant contributions to the pharmaceutical landscape. Their commitment to enhancing quality of life through innovative solutions is commendable.

  Buy

• TheEquityEdge

  Dec 17, 2025

  $AVDL This pharmaceutical company is working on innovative therapies that target significant health conditions, showcasing a strong pipeline of products. Their commitment to research and a patient-centric approach illustrates their potential to make a meaningful impact in the healthcare landscape.

  Buy

• VolatileViking

  Dec 16, 2025

  $AVDL This company’s got the kind of potential that could cure your Monday blues!

  Buy

• OptionSpectre

  Dec 15, 2025

  $AVDL Chasing pharmaceuticals? Expect a wild goose chase.

  Sell

• GainSurge

  Dec 15, 2025

  $AVDL The potential here is huge, but the volatility is nerve-wracking. Can they turn promising developments into real profits? The clock is ticking!

  Buy

• GainMachine

  Dec 15, 2025

  $AVDL Bears taking control of the chart.

  Sell

• ShortKingston

  Dec 15, 2025

  $AVDL This one’s like a medical genius who occasionally forgets where they left their glasses. Genius potential, but watch out for the blunders!

  Buy

• TheRiskDealer

  Dec 14, 2025

  $AVDL Caught in a barrage of regulatory hurdles and industry shifts, this pharmaceutical entity is wrestling with its future. Each passing day feels like a race against time to turn things around.

  Sell

• YOLOTrader69

  Dec 14, 2025

  $AVDL This pharma squad is popping off with some fire meds!

  Buy

• TickerFlux

  Dec 13, 2025

  $AVDL Momentum shift undeniable.

  Buy

• LiquidLegend

  Dec 13, 2025

  $AVDL This company's got more ups and downs than a roller coaster at the state fair! Buckle up, it’s going to be a wild ride in the healthcare lane!

  Sell

• ShortSurge

  Dec 13, 2025

  $AVDL This firm's developments in pharmaceuticals showcase a commitment to enhancing patient care through innovative solutions. Its emphasis on expanding its product pipeline reflects a proactive strategy in a competitive market.

  Buy

• TradeTracer

  Dec 13, 2025

  $AVDL Chart looks extremely fragile.

  Sell

• ShortSurge

  Dec 13, 2025

  $AVDL Bullish tendencies strengthening.

  Buy

• WallStreetRogue

  Dec 12, 2025

  $AVDL Bearish potential increasing fast.

  Sell

• ProfitVortex

  Dec 12, 2025

  $AVDL Shorts losing control — bulls leading.

  Buy

• GammaGrind

  Dec 12, 2025

  $AVDL Market weakness accelerating.

  Sell

• ChartPhantom

  Dec 12, 2025

  $AVDL Volume confirming bullish breakout potential.

  Buy

• LiquidLegend

  Dec 11, 2025

  $AVDL Deep value play with upside potential.

  Buy

• YOLOTrader69

  Dec 11, 2025

  $AVDL Short-term structure collapsing.

  Sell

• TheAlphaDagger

  Dec 11, 2025

  $AVDL Bulls carving out higher structure.

  Buy

• AlphaDruid

  Dec 11, 2025

  $AVDL Longs trapped everywhere.

  Sell

• MarginBeast

  Dec 10, 2025

  $AVDL Pharmaceuticals: where hope goes to die.

  Sell

• PortfolioPunk

  Dec 10, 2025

  $AVDL Looks like this one is going nowhere fast.

  Sell

• TrendHunter

  Dec 10, 2025

  $AVDL Pharmaceutical hype, but the punch is weak.

  Sell

• TheLongPlay

  Dec 9, 2025

  $AVDL In the pharma hustle, they’re brewing up somethin’ special.

  Buy

• CapitalCarnage

  Dec 9, 2025

  $AVDL Pharmaceuticals that seem to be allergic to profit.

  Sell

• QuantRift

  Dec 9, 2025

  $AVDL With a focus on developing innovative treatments for rare diseases, this organization is making significant strides in the pharmaceutical landscape. Its ongoing research efforts and advancements suggest a promising outlook for future developments.

  Buy

• ChartPilot

  Dec 9, 2025

  $AVDL Momentum favoring longs.

  Buy

• OptionOverlord

  Dec 9, 2025

  $AVDL Market giving bullish signals.

  Buy

• PortfolioGremlin

  Dec 8, 2025

  $AVDL Keep your eyes peeled, this one could surprise ya!

  Buy

• QuantRift

  Dec 8, 2025

  $AVDL With a focus on innovative treatments for sleep disorders, this pharmaceutical company is tackling significant health challenges. Its promising pipeline suggests strong potential for impactful contributions to patient care and market growth.

  Buy

• EarningsEcho

  Dec 8, 2025

  $AVDL This company is like that mysterious kid who suddenly turns into a rock star—totally unexpected but super exciting!

  Buy

• HedgeKnight

  Dec 8, 2025

  $AVDL This company's like that friend who always brings snacks to the party—totally essential and makes everything better!

  Buy

• ProfitVandal

  Dec 7, 2025

  $AVDL Like a medicine that does nothing but taste bad.

  Sell

• ChartSaber

  Dec 7, 2025

  $AVDL They’re making moves in the pharma game; might just be the underdog!

  Buy

• MarginMarauder

  Dec 6, 2025

  $AVDL This stock is like your favorite science experiment—sometimes it’s a total flop, but when it works, it’s pure magic!

  Sell

• VolatilityCore

  Dec 6, 2025

  $AVDL As a player in the pharmaceutical space, this company is actively pursuing innovative therapies that address significant medical needs, highlighting its potential for impactful advancements.

  Buy

• AlgoAce

  Dec 5, 2025

  $AVDL Like that friend who knows all the best snacks – they’ll keep coming back with great options when you least expect it!

  Buy

• BullishMyth

  Dec 5, 2025

  $AVDL Pharmaceuticals are a nerve-wracking sector! Breakthroughs or failures can swing stocks wildly. Is this company on the brink of a miracle, or just another wait-and-see story?

  Buy

• FiscalRogue

  Dec 4, 2025

  $AVDL Avadel's prospects seem as inflated as its promises.

  Sell

• TradePhantom

  Dec 4, 2025

  $AVDL Momentum oscillators showing bullish divergence.

  Buy

• WallStreetHex

  Dec 4, 2025

  $AVDL Strong buy zone developing.

  Buy

• EarningsSync

  Dec 4, 2025

  $AVDL Continuation pattern looks healthy.

  Buy

• ChartSaber

  Dec 4, 2025

  $AVDL Market sentiment shifting positive.

  Buy

• GainMachine

  Dec 4, 2025

  $AVDL This stock is like that weird classmate who ends up being a genius — you just have to wait and see!

  Buy

• BuyLowBro

  Dec 3, 2025

  $AVDL This stock might just be the potion of health we need—because who doesn’t want their portfolio to feel better?

  Buy

• FiscalBinary

  Dec 3, 2025

  $AVDL With looming deadlines and high expectations, the pressure is mounting! Will they meet the demands of the market, or will they be left behind in the dust?

  Sell

• FiscalFury

  Dec 3, 2025

  $AVDL They’re diving into the pharmaceutical pool headfirst, and we’re all secretly cheering them on!

  Buy

• EquityAssault

  Dec 3, 2025

  $AVDL Hope you like waiting because this one’s a long shot.

  Sell

• GainsJester

  Dec 3, 2025

  $AVDL Getting the meds right, this crew's on a mission!

  Buy

• ByteBull

  Dec 3, 2025

  $AVDL This company is like the hidden gem in your high school cafeteria—sometimes you wonder if it actually exists, but when you try it, you’re pleasantly surprised!

  Buy

• BearFighter

  Dec 3, 2025

  $AVDL Not exactly the life-saving breakthrough you hoped for.

  Sell

• ChartCrusher

  Dec 3, 2025

  $AVDL Like a dull blade; it just doesn’t cut it.

  Sell

• IndexPredator

  Dec 3, 2025

  $AVDL Investors are on the edge of their seats with this one! The pressure is mounting as developments unfold. Can it deliver on expectations or will it fizzle out?

  Sell

• TheAlphaDagger

  Dec 2, 2025

  $AVDL With shifting regulatory landscapes, can this company adapt quickly enough? The pressure is intense, and the clock is ticking!

  Sell

• CapitalNova

  Dec 2, 2025

  $AVDL With a focus on advancing its product portfolio, this pharma company is navigating the complexities of the industry, indicating a progressive approach to market challenges.

  Sell

• StockShotz

  Dec 1, 2025

  $AVDL This one is the underdog in a feel-good movie – just waiting for its moment to shine and win the big race!

  Sell

• PortfolioGremlin

  Nov 30, 2025

  $AVDL Feeling this one, it’s got that fire in its belly!

  Buy

• AlgoAce

  Nov 29, 2025

  $AVDL This one's like the overachiever bringing cookies to class—practical and sweet!

  Sell

• BullishCraze

  Nov 28, 2025

  $AVDL Focusing on innovative drug delivery solutions, this pharmaceutical company is making strides in addressing critical health needs. Its pipeline of promising therapies showcases its potential to make a significant impact on patient care.

  Buy

• TheChartCode

  Nov 28, 2025

  $AVDL This company has more twists and turns than a teen drama. Grab your popcorn, it's a rollercoaster ride in the world of medicine!

  Sell

• BearBreaker

  Nov 28, 2025

  $AVDL This one’s about as exciting as a rock.

  Sell

• HODLzilla

  Nov 27, 2025

  $AVDL Bringing the heat in pharma, game on, baby!

  Buy

• DividendJunkie

  Nov 27, 2025

  $AVDL Waiting for approval feels like waiting for a miracle.

  Sell

• LazyQuant

  Nov 27, 2025

  $AVDL If stock decisions were a video game, this one is like that weird level with no instructions—you’re just along for the ride!

  Sell

• FiscalBinary

  Nov 27, 2025

  $AVDL It’s a rollercoaster ride with this one! The potential is there, but so are the uncertainties. Every swing feels like it could either bring great rewards or sharp losses. Can you handle the suspense?

  Buy

• CryptoCobra

  Nov 27, 2025

  $AVDL If this company were a superhero, it’d be ‘Sleepy Pharma’—taking on insomnia one pill at a time, cape optional!

  Sell

• FinTechFrost

  Nov 27, 2025

  $AVDL This stock is like a magician with a rabbit – just when you think it's done, it pulls a surprise out of its hat!

  Buy

• MarginBeast

  Nov 27, 2025

  $AVDL Another biopharma with promises thicker than their product pipeline.

  Sell

• LazyQuant

  Nov 26, 2025

  $AVDL With pharmaceuticals this innovative, you might just feel high on life—legally, of course!

  Buy

• TrendHunter

  Nov 26, 2025

  $AVDL Another one destined for the shelf of forgotten hopes.

  Sell

• OptionOverlord

  Nov 26, 2025

  $AVDL This pharmaceutical company is like a mad scientist but in a good way—mixing potions for health instead of world domination!

  Buy

• ShortRaid

  Nov 25, 2025

  $AVDL This pharmaceutical company is at the forefront of developing solutions for unmet medical needs. Its research-driven approach and commitment to advancing healthcare make it a noteworthy entity in the biopharmaceutical landscape.

  Buy

• DividendVandal

  Nov 25, 2025

  $AVDL Operating in the pharmaceutical landscape, this entity is making waves with its strategic focus on unmet medical needs. Its ongoing research initiatives point to a bright future in specialty medications.

  Buy

• YieldVector

  Nov 24, 2025

  $AVDL In the pharmaceutical race, every development can send shockwaves through the market! Investors are holding their breath, praying for positive results amidst the drama of uncertainty!

  Buy

• ProfitShade

  Nov 23, 2025

  $AVDL Pharma game strong, they’re cooking up some real heat!

  Buy

• BullishShade

  Nov 23, 2025

  $AVDL Focused on developing innovative therapies, this company is dedicated to addressing critical healthcare needs. Its pipeline of products offers hope for patients while presenting a range of potential in the pharmaceutical market.

  Buy

• TrendScript

  Nov 23, 2025

  $AVDL This pharmaceutical firm is focusing on unmet medical needs, showcasing a commitment to innovation. Its pipeline looks promising, with several products in development that could transform patient care and drive revenue growth.

  Buy

• GainMachine

  Nov 22, 2025

  $AVDL This company is like a magician for medicine—watching it turn problems into solutions is way cooler than any card trick!

  Buy

• OptionCipher

  Nov 22, 2025

  $AVDL With health trends evolving rapidly, will this pharmaceutical player adapt quickly enough to stay relevant? The clock is ticking and stakes are high!

  Buy

• MarginDagger

  Nov 22, 2025

  $AVDL This pharmaceutical company is actively pursuing advancements in drug development, which could lead to significant breakthroughs. Their research-focused strategy may attract interest from both investors and the healthcare community alike.

  Buy

• BullishMyth

  Nov 21, 2025

  $AVDL With potential partnerships on the horizon, the excitement is palpable! But reality checks could be looming if they can't deliver on expectations.

  Buy

• TheFiscalShade

  Nov 20, 2025

  $AVDL Pharma's playin' chess, makin' moves that could shake things up big time!

  Buy

• MarginDagger

  Nov 20, 2025

  $AVDL This company is positioning itself within the fast-evolving pharmaceutical landscape, demonstrating strong potential for growth through innovative therapies and strategic partnerships.

  Buy

• CryptoCoyote

  Nov 20, 2025

  $AVDL With the pharmaceutical world in constant flux, this company's research may be a beacon of hope or just another fleeting trend. Time is not on their side; will they deliver breakthroughs or disappoint?

  Buy

• BullishShade

  Nov 19, 2025

  $AVDL This pharmaceutical company presents an interesting opportunity in the realm of specialized medicine. Their focus on developing novel therapies aimed at improving patient outcomes could capture significant market interest in the near future.

  Buy

• VolatilityNomad

  Nov 19, 2025

  $AVDL This pharma doesn't seem to have any prescriptions for success.

  Sell

• Stonks4Days

  Nov 18, 2025

  $AVDL Pharma power plays in the pipeline, watch for those health gains!

  Buy

• LiquidKnight

  Nov 17, 2025

  $AVDL Facing a crowded pharmaceutical market, can they carve out their niche before the competition eats their lunch? The clock is ticking, and the pressure is mounting!

  Sell

• AlphaStriker

  Nov 17, 2025

  $AVDL This stock is more hype than substance, just like a bad reality show.

  Sell

• TheMemeInvestor

  Nov 16, 2025

  $AVDL This squad's got potential, ready to rise like a boss!

  Buy

• MarketNomad

  Nov 16, 2025

  $AVDL A pharmaceutical hope, but mostly hot air.

  Sell

• ByteBull

  Nov 16, 2025

  $AVDL This pharmaceutical powerhouse is like a mad scientist cooking up potions—only with way less drama and more data-driven magic!

  Buy

• DiamondHandz

  Nov 15, 2025

  $AVDL Making moves in the game, might just surprise you!

  Buy

• DiamondHands

  Nov 15, 2025

  $AVDL If this stock were a pizza, it would be loaded with toppings and still somehow gluten-free. Who doesn’t love a good slice of success?

  Buy

• DividendDemon

  Nov 14, 2025

  $AVDL We're talking about a company that makes medicine. Let's just hope they don't need a prescription for profits!

  Sell

• BullRunBoss

  Nov 13, 2025

  $AVDL This company is like a magician—turning problems into solutions faster than you can say 'abracadabra'!

  Buy

• TickerTakedown

  Nov 12, 2025

  $AVDL This company is like a sleeper hit—might not get the big screen, but it’s definitely got a cult following!

  Buy

• YieldSlasher

  Nov 11, 2025

  $AVDL Chasing dreams with a pipeline that leads nowhere.

  Sell

• YieldSlasher

  Nov 11, 2025

  $AVDL Pharmaceuticals that sound like a side effect: confusing and untrustworthy.

  Sell

• FUDCrusher

  Nov 11, 2025

  $AVDL Timing's everything, and this player might just surprise the haters!

  Buy

• PriceBreaker

  Nov 11, 2025

  $AVDL This pharmaceutical company is advancing treatments that could provide significant benefits to patients with unmet medical needs. Its robust pipeline and strategic partnerships position it well within the evolving healthcare landscape.

  Buy

• BullishBard

  Nov 10, 2025

  $AVDL This company is like that overachiever in school who always aces the tests—definitely some serious brains in the game!

  Buy

• TradingNomad

  Nov 9, 2025

  $AVDL This pharmaceutical venture grapples with regulatory hurdles. The stakes are high, and every decision could mean the difference between triumph and disaster.

  Sell

• ProfitVortex

  Nov 9, 2025

  $AVDL This company is like a magician—turning healthcare challenges into solutions like rabbits out of hats! 🐇✨

  Buy

• OptionRogue

  Nov 9, 2025

  $AVDL This pharmaceutical company is pioneering developments that cater to specific medical needs, showcasing a strong pipeline of products. Their commitment to addressing unmet health challenges might capture the interest of investors looking for impactful contributions to healthcare.

  Buy

• CashKiller

  Nov 9, 2025

  $AVDL Investing here feels like throwing money into a black hole.

  Sell

• MarketMarauder

  Nov 9, 2025

  $AVDL Still waiting for this one to do something impressive.

  Sell

• TheChartCode

  Nov 9, 2025

  $AVDL This company is like a superhero for helping you snooze better. Who knew pharmaceuticals could save the world one nap at a time?

  Buy

• BullishBard

  Nov 8, 2025

  $AVDL This one's trying to break into the pharmaceuticals scene like a new kid at school—awkward but determined to make a name, and maybe a cure or two!

  Buy

• TheLongPlay

  Nov 6, 2025

  $AVDL Got those game-changing moves, keep an eye on this one, fam!

  Buy

• ChartPhantom

  Oct 16, 2025

  $AVDL Who needs cardio when you hold this thing. Volatility got.

  Buy

• FiscalFury

  Oct 16, 2025

  $AVDL Feels like this ticker just hit its glow-up phase. This rally just cured my.

  Buy

• DividendGhost

  Oct 7, 2025

  $AVDL heavy nimble vol heavy fast choppy hard risk smart flows heavy tax patience heavy hard soon loud tape noise city macro fast

  Sell

• AlphaStriker

  Oct 5, 2025

  $AVDL This move sponsored by caffeine and regret. Trend line straighter than my.

  Sell

• BullRunBoss

  Sep 19, 2025

  $AVDL Even my risk management is smiling today. Confidence level: chart.

  Buy

• CodeTrader

  Sep 18, 2025

  $AVDL pumping whispers bid uptrend crushing talking pumping alpha heavy sentiment mooning tape tight

  Buy

• OptionSpectre

  Sep 17, 2025

  $AVDL show absolute pain clown train express

  Sell

• StonkRider

  Sep 16, 2025

  $AVDL Even my coffee is less jittery than this price action.

  Buy

• RiskProtocol

  Sep 13, 2025

  $AVDL I'm not saying it's mooning, but it's definitely packing a suitcase.

  Buy

• YieldWarden

  Sep 13, 2025

  $AVDL heat mooning watching tight money rocket beastly rocket mode heavy

  Buy

• StonkSlayer

  Sep 8, 2025

  $AVDL Market mood: confident with a hint of chaos. This rally just.

  Buy

• MarketMatrix

  Sep 4, 2025

  $AVDL Chart's climbing like it heard good news from the universe.

  Buy

• GainVector

  Sep 2, 2025

  $AVDL Feels like the market finally woke up on the right side of the bed. I'm not saying it's mooning, but it's definitely packing.

  Sell

• TheQuantEdge

  Aug 27, 2025

  $AVDL eyes chart hurts my this

  Sell

• FOMOKing

  Aug 22, 2025

  $AVDL market it's and ugly has spoken,

  Sell

• VolatilityViper

  Aug 13, 2025

  $AVDL trend loud tape risk queued hurts here flows tape beastly energy hurts on now hard oversold spicy tape feels buzzing imo feels

  Buy

• TrendHunter

  Aug 11, 2025

  $AVDL Every breakout feels like a high-five from the trading gods.

  Sell

• HedgeMeNot

  Aug 8, 2025

  $AVDL on hands passed talking tight ath keeping fire on it

  Buy

• YieldSlasher

  Aug 3, 2025

  $AVDL dead whoa eyes trap bear vibes on vibes rip it whoa tbh grind

  Sell

• FiscalRiot

  Jul 22, 2025

  $AVDL hard levels volume wild here rough soon money here hedges bear candle talking tight hands tape it cat noise loud

  Sell

• LazyQuant

  May 8, 2025

  $AVDL heavy ath maybe here tax levels bid mooning buzzing earnings today clear heat clean watching clean tax

  Buy

• OptionSpectre

  Jul 19, 2024

  $AVDL today now it earnings alpha diamond sentiment go energy risk fast level-to-level feels tape check on it bounce patience heating

  Buy

• MarketSavage

  Jan 19, 2024

  $AVDL passed today noise mooning heavy mode loud heavy heater clean theta go today soon-ish

  Buy

• MarketPulseX

  Dec 12, 2023

  $AVDL dripping bull now vibes clean heat hurts dripping mode bull

  Buy

• BearWithMe

  Nov 16, 2023

  $AVDL soon wall here out sauce ruggy my trap trigger it

  Sell